logo
Court grants time to arms dealer Sanjay Bhandari to avail legal remedy against order declaring him fugitive

Court grants time to arms dealer Sanjay Bhandari to avail legal remedy against order declaring him fugitive

India Gazette2 days ago
New Delhi [India], July 12 (ANI): Delhi's Rouse Avenue court on Saturday granted time to Arms dealer Sanjay Bhandari to exhaust statutory legal remedy against the order declaring him a fugitive economic offender.
Bhandari was declared a fugitive economic offender on July 5. The second step is the confiscation of his properties.
Special judge Sanjay Jindal granted time to Bhandari's counsel till August 2.
Meanwhile, the court adjourned the hearing on the Enforcement Directorate (ED)'s plea seeking confiscation of Sanjay Bhandari's properties.
Bhandari's counsel sought time to challenge the order declaring Bhandari a fugitive economic offender.
Special Counsel Zoheb Hossain, along with Special Public Prosecutor (SPP) Naveen Kumar Matta and Mohd Faizan, appeared for the ED.
It was submitted that notices have already been served on the application. Three noticees have already filed their reply.
Zoheb Hosain mentioned before the court that there is a list which includes properties to be included in India, Dubai, and the UK, benami property in Noida and Gurugram, a series of bank accounts in his and his wife's name, jewellery and cash, immovable property in India in Vasant Vihar, Panchsheel shopping complex, and property in Shahpur Jat.
On the other hand, counsel for Bhandari sought time on the ground that there is a 30-day time limit to challenge the order before the high court. He prayed to adjourn the time he exhausted his legal remedy against the order.
It was also submitted by the counsel that others have an opportunity to make their submissions on the application. 'I have a statutory remedy. Let me exhaust my statutory remedy. The properties mentioned are already attached by the ED,' the counsel said.
Zoheb Hossain opposed the submissions by submitting that no adjournment can be sought on the ground of filing an appeal. He said that Bandari's Counsel cannot make submissions on behalf of other notices.
On July 5, a Delhi special court declared UK-based arms dealer Sanjay Bhandari a fugitive Economic Offender under the Fugitive Economic Offenders (FEO) Act, in connection with an income tax case involving undisclosed foreign assets.
Additional Sessions Judge Sanjeev Aggarwal passed the order following a plea by the Enforcement Directorate (ED), which has alleged that Bhandari had deliberately evaded Indian legal proceedings and possessed foreign assets exceeding Rs 100 crore. The agency emphasised that the UK court's refusal to extradite Bhandari had no bearing on the current proceedings, which are independent and governed by Indian law.
Bhandari, however, contested the ED's plea, arguing that his residence in the UK is lawful and backed by a ruling from the London High Court, which denied his extradition, citing concerns over his safety in Tihar jail. His counsel, senior advocate Maninder Singh, claimed the ED's application was vague, lacked jurisdiction, and failed to meet the legal threshold under the FEO Act.
Singh had further argued that the monetary value of the alleged offence did not exceed Rs 100 crore, referencing a 2020 submission by the Income Tax Department. He also pointed out that the UK High Court had discharged Bhandari, and no fresh warrants were pending against him.
The UK High Court had earlier blocked Bhandari's extradition on human rights grounds, citing risks of extortion and violence in Indian custody. The Indian government's subsequent attempt to challenge the decision in Britain's Supreme Court was also rejected. (ANI)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

India begins crucial week-long trade negotiations with US
India begins crucial week-long trade negotiations with US

Indian Express

time13 minutes ago

  • Indian Express

India begins crucial week-long trade negotiations with US

Days after US President Donald Trump announced fresh reciprocal tariff rates of up to 50 per cent for scores of countries, including the European Union, Canada, Brazil and ASEAN among others, Indian negotiators have begun a fresh round of talks in Washington to clinch a deal before August 1. 'India's aim is to sign a bilateral trade deal by the end of the year. The week-long negotiations have begun and the interim trade deal will depend on the willingness of both sides. If substantial agreement is reached, an interim agreement can be reached,' a senior government official said on Monday. Another official, seeking anonymity, said that India is in an advantageous position compared to other countries, particularly its Asian peers, and that the likelihood of India reaching a trade deal with the US is high. The ongoing round of negotiation comes less than 10 days after Indian officials, led by Special Secretary Rajesh Agarwal, returned from Washington on July 4. The Indian Express had reported that agriculture has been a major sticking point in the negotiations, particularly because India has adopted an unwavering stance on this sector. The US maintains that the August 1 cut-off date is not a new deadline but an outer limit for countries to 'speed things up', and that this strategy has helped bring trading partners such as the European Union on board. US Treasury Secretary Scott Bessent, when asked in a TV interview if there was a playbook for the US tariffs actions, said: 'The playbook is to apply maximum pressure. You know, we saw that the EU was very slow in coming to the table. Three weeks ago, on a Friday morning, President Trump threatened 50 per cent tariffs. And within a few hours, five of the European national leaders had called him. Ursula von der Leyen, the head of the EU, was on the phone and the EU is making very good progress. They were off to a slow start.' The threat from the Trump administration is that if the August 1 deadline is not adhered to, those countries go back to the April 2 tariff levels. Most of them are minor trading partners of the US and are likely outside America's 18 important trading relationships that account for 95 per cent of the country's trade deficit. Ravi Dutta Mishra is a Principal Correspondent with The Indian Express, covering policy issues related to trade, commerce, and banking. He has over five years of experience and has previously worked with Mint, CNBC-TV18, and other news outlets. ... Read More

Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute
Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute

Mint

time20 minutes ago

  • Mint

Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute

Sun Pharma on Monday announced it has settled a patent row with American biopharma company Incyte Corporation over its hair-loss drug, paving the way for its launch in the US. The Mumbai-based drugmaker, embroiled in the lawsuit since last year, launched the specialty drug in the world's largest pharmaceutical market on Monday. Leqselvi (oral deuruxolitinib) is indicated for treatment of adults with severe alopecia areata. Under the terms of settlement and licensing agreement, the two companies will seek a dismissal of the pending litigation in the United States District Court for the District of New Jersey, the company said in a release. Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation. Incyte has also granted a limited, non-exclusive licence to Sun to US patents no. 9,662,335 and other related patents. This licence covers oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, the company said. In return, Sun will pay Incyte an upfront amount, as well as ongoing royalty payments until expiry of the patents. The company did not reveal other specific terms of the settlement. In April 2025, Sun Pharma received a favourable ruling from the US Court of Appeals for the Federal Circuit, which vacated a preliminary injunction on Leqselvi's launch, lifting restrictions on the launch. Sun received approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator's approval, Incyte Corporation filed a patent infringement lawsuit against Sun Pharma, alleging that Leqselvi infringed upon its existing patents, delaying the launch. In November 2024, the US District Court of New Jersey granted a preliminary injunction, halting Leqselvi's launch in the US until the lawsuit was resolved. Sun Pharma on Monday announced the launch of Leqselvi in the US, in a separate release. The drug will be available for prescription in 8mg tablets in the country. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," said Richard Ascroft, CEO, Sun Pharma North America, in the release. Leqselvi demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks. Leqselvi is expected to be a $200 million opportunity for Sun Pharma in 3-4 years after launch, according to brokerage Elara Capital. Sun Pharma's shares ended 0.58% higher at ₹ 1,681.70 apiece on NSE on Monday.

Corporate Bond issuances hit 4-year high in Q1, surpass Rs 3 lakh crore mark
Corporate Bond issuances hit 4-year high in Q1, surpass Rs 3 lakh crore mark

Hans India

time20 minutes ago

  • Hans India

Corporate Bond issuances hit 4-year high in Q1, surpass Rs 3 lakh crore mark

New Delhi: The first quarter of the current financial year (Q1 FY26) has been a very productive period for the corporate bond market as the issuances have crossed the Rs 3 lakh crore mark, the highest in the last 4 years, according to a report on Monday. In the April-June quarter, issuances reached a peak of Rs 3.27 lakh crore, representing a 42.7 per cent increase over the Rs 2.29 crore recorded in the same quarter the previous year, a report from Bank of Baroda (BoB) said. Debt issuances have seen a mixed pattern in the said period. It has risen from Rs 1.44 lakh crore in 2022 (Q1) to Rs 2.86 lakh crore in 2023 and then slowed down to Rs 2.29 lakh crore in 2023, the first quarter. The development indicates an increase in potential investment, as most debt raised in the market is for financing investment, according to the report. The financial services segment has been the dominant player in issuance, as it remained a major source of funding for its lending operations in the first quarter for the past three years. The sector had accounted for more than three-quarters of the issuances in 2023 (79.2 per cent) and 2024 (74.6), but came down to 62 per cent in 2025, the data showed. Manufacturing, electricity, and diversified groups of companies all saw a sharper increase in issuances from other sectors. Meanwhile, the weighted average yield on corporate bonds for AAA and AA-rated bonds tended to have more favourable rates compared with bank borrowings, where the weighted average lending rate (WALR) on fresh loans tended to be higher. In Q1 2025, bank WALR was lower than the 10-year yield for an AA rated bond, the report said. Corporate bond spreads for AAA paper for 10 years are presently ruling at between 80-90 bps, while it is around 200 bps for AA-rated paper, the report noted. The low interest environment will provide a further boost to this segment, the report said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store